Accessibility Menu
Racura Oncology logo

Racura Oncology(ASX) RAC

Market CapA$391.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+653%
5 Year-36%
1 Year+71%
1 Month-11%
A$2.00
-0.75%
-0.01Today
Racura Oncology last closing stock price
MetricPriceDate
Last closeAUD 2.002026-08-14
Racura Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 2.002026-08-07
1 month-10.54%AUD 2.232026-07-15
3 month-27.72%AUD 2.762026-05-15
Year to date-26.92%AUD 2.732025-12-31
1 year+71.24%AUD 1.172025-08-14
3 year+120.44%AUD 0.912023-08-15
5 year-36.06%AUD 3.122021-08-13
Since inception+652.83%AUD 0.272016-07-13

Racura Oncology Financials at a Glance

Market Cap

A$391.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$6.88M

Net Income (TTM)

-A$17.04M

EPS (TTM)

-A$0.05

P/E Ratio

-37.15

Dividend

A$0.00

Beta (Volatility)

0.03 (Low)

Price

A$2.00

Volume

52,655

Open

A$2.04

Previous Close

A$2.00

Daily Range

A$1.99 - A$2.04

52-Week Range

A$1.17 - A$4.90

Estimated Earnings Date

Sep 1, 2026

RAC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Racura Oncology

Race Oncology Limited is a precision oncology company based in Sydney, Australia, focused on developing its lead therapeutic, Zantrene. This small molecule compound is currently in Phase II/III clinical trials, targeting various cancers, including melanoma and acute myeloid leukaemia.

Products and Services
  • Zantrene, a small molecule compound targeting cancer treatment
  • Active preclinical research programs in collaboration with universities
  • Strategic alliances for drug formulation assessments
Growth Outlook
  • Ongoing Phase II/III trials for Zantrene may lead to significant market opportunities
  • Partnerships with leading universities enhance research capabilities
  • Potential expansion into new cancer treatment areas increases growth prospects
Financial Highlights
  • Recent quarterly revenue of AUD 0, indicating ongoing investment in R&D
  • Cash and cash equivalents of AUD 20.94 million as of December 2025
  • Trailing twelve months (TTM) gross profit margin of 49.76%, reflecting operational efficiency
Race Oncology Limited is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company’s lead product, Zantrene, is undergoing critical clinical trials, which could pave the way for new treatment options in oncology. Collaborations with academic institutions bolster its research efforts, potentially leading to advancements in drug formulations and applications. Financially, the company is currently investing heavily in research and development, as evidenced by its recent quarterly results showing no revenue but significant cash reserves. The gross profit margin indicates a strong potential for operational efficiency as the company progresses. With a solid cash position, Race Oncology Limited is well-equipped to navigate the challenges of clinical development and market entry.
AI Generated • Aug 2, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Daniel Tillett, PhD

Website

www.raceoncology.com

Headquarters

Sydney, NSW 2000, AU

RAC Financials

Key Financial Metrics (TTM)

Gross Margin

49.76%

Operating Margin

-1294.94%

Net Income Margin

-1190.78%

Return on Equity

-47.44%

Return on Capital

-23.56%

Return on Assets

-37.91%

Earnings Yield

-2.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$391.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

196.07M

Volume

52.66K

Avg. Volume

113.24K

Financials (TTM)

Gross Profit

A$4.50M

Operating Income

-A$17.39M

EBITDA

-A$17.97M

Operating Cash Flow

-A$8.15M

Capital Expenditure

-A$3.00

Free Cash Flow

-A$8.15M

Cash & ST Invst.

A$20.94M

Total Debt

A$0.00

Racura Oncology Performance Analysis

Racura Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Racura Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-79.2%
Q22024-12-31531.2%
Q42025-06-30-85.0%
Q22025-12-31-100.0%
Racura Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.07N/A
20232023-06-30AUD -0.06-15.6%
20242024-06-30AUD -0.0836.1%
20252025-06-30AUD -0.03-66.9%
Racura Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-42.5%
Q22024-12-31105.3%
Q42025-06-30-1284.6%
Q22025-12-3124.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$140.60K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

A$391.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$78.23M

N/A

Employees

5

N/A

Net Income

-A$4.10M

+27.6%

EBITDA

-A$5.52M

+42.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$20.94M

+52.7%

Total Debt

A$0.00

N/A

Accounts Receivable

A$32.30K

-99.2%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-37.91%

N/A

Return on Invested Capital

-43.24%

N/A

Free Cash Flow

-A$2.19M

+73.2%

Operating Cash Flow

-A$2.19M

+73.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACL.AXAustralian Clinical Labs Limited
A$2.35-0.42%
CGS.AXCogstate Limited
A$2.80+2.19%
OCA.AXOceania Healthcare Limited
A$0.66+0.76%
CUV.AXClinuvel Pharmaceuticals Limited
A$9.55-0.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About RAC

What is the current price of Racura Oncology?

Racura Oncology is trading at A$2.00 per share.

What is the 52-week range for Racura Oncology?

Over the past 52 weeks, Racura Oncology has traded between A$1.17 and A$4.90.

How much debt does Racura Oncology have?

As of the most recent reporting period, Racura Oncology reported total debt of A$0.00.

How much cash does Racura Oncology have on hand?

Racura Oncology reported A$13.67M in cash and cash equivalents in its most recent financial results.

What is Racura Oncology’s dividend yield?

Racura Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services